Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Trial Profile

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2018

At a glance

  • Drugs Immune globulin (Primary) ; Immune globulin (Primary)
  • Indications Allotransplant rejection; Ataxia; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Peripheral nervous system diseases
  • Focus Adverse reactions
  • Sponsors Baxalta; Shire
  • Most Recent Events

    • 23 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 15 Feb 2018 Planned End Date changed from 31 Jan 2020 to 30 Jun 2020.
    • 15 Feb 2018 Planned primary completion date changed from 31 Jan 2020 to 30 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top